Recombinant Activated Factor VII: The Controversial Conundrum Regarding Its Off-Label Use

被引：14
作者：
Karkouti, Keyvan [1 ]
Levy, Jerrold H. [2 ]
机构：
[1] Univ Toronto, Univ Hlth Network, Toronto Gen Hosp, Dept Anesthesiol & Hlth Policy Management & Evalu, Toronto, ON M5G 2C4, Canada
[2] Emory Univ, Dept Anesthesiol, Sch Med Cardiothorac Anesthesiol & Crit Care Emor, Atlanta, GA 30322 USA
来源：
ANESTHESIA AND ANALGESIA | 2011年 / 113卷 / 04期
关键词：
CARDIAC-SURGERY; HEALTHY-SUBJECTS; REVERSAL; WARFARIN; SAFETY; RFVIIA;
D O I：
10.1213/ANE.0b013e318228c6a9
中图分类号：
R614 [麻醉学];
学科分类号：
100217 ;
摘要：
引用
收藏
页码：711 / 712
页数：2
相关论文
共 15 条
  • [1] A Hemorrhage of Off-Label Use
    Avorn, Jerry
    Kesselheim, Aaron
    [J]. ANNALS OF INTERNAL MEDICINE, 2011, 154 (08) : 566 - 567
  • [2] Assessment, Mechanisms, and Clinical Implication of Variability in Platelet Response to Aspirin and Clopidogrel Therapy
    Ben-Dor, Itsik
    Kleiman, Neal S.
    Lev, Eli
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2009, 104 (02) : 227 - 233
  • [3] Safety and Efficacy of Recombinant Activated Factor VII A Randomized Placebo-Controlled Trial in the Setting of Bleeding After Cardiac Surgery
    Gill, Ravi
    Herbertson, Mike
    Vuylsteke, Alain
    Olsen, Peter Skov
    von Heymann, Christian
    Mythen, Monty
    Sellke, Frank
    Booth, Frank
    Schmidt, Thomas Andersen
    [J]. CIRCULATION, 2009, 120 (01) : 21 - +
  • [4] NovoSeven® as a universal haemostatic agent
    Hedner, U
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 : S107 - S111
  • [5] Mechanism of action, development and clinical experience of recombinant FVIIa
    Hedner, Ulla
    [J]. JOURNAL OF BIOTECHNOLOGY, 2006, 124 (04) : 747 - 757
  • [6] Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose
    Holland, Lorne
    Warkentin, Theodore E.
    Refaai, Majed
    Crowther, Mark A.
    Johnston, Marilyn A.
    Sarode, Ravindra
    [J]. TRANSFUSION, 2009, 49 (06) : 1171 - 1177
  • [7] Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case-control analysis
    Karkouti, K
    Beattie, WS
    Wijeysundera, DN
    Yau, TM
    McCluskey, SA
    Ghannam, M
    Sutton, D
    van Rensburg, A
    Karski, J
    [J]. TRANSFUSION, 2005, 45 (01) : 26 - 34
  • [8] Comprehensive Canadian review of the off-label use of recombinant activated factor VII in cardiac surgery
    Karkouti, Keyvan
    Beattie, W. Scott
    Arellano, Ramiro
    Aye, Tim
    Bussieres, Jean S.
    Callum, Jeannie L.
    Cheng, Davy
    Heinrich, Lee
    Kent, Blaine
    Lee, Trevor W. R.
    MacAdams, Charles
    Mazer, C. David
    Muirhead, Brian
    Rochon, Antoine G.
    Rubens, Fraser D.
    Sawchuk, Corey
    Wang, Shaohua
    Waters, Terrence
    Wong, Bill I.
    Yau, Terrence M.
    [J]. CIRCULATION, 2008, 118 (04) : 331 - 338
  • [9] Safety of Recombinant Activated Factor VII in Randomized Clinical Trials.
    Levi, Marcel
    Levy, Jerrold H.
    Andersen, Henning Friis
    Truloff, David
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (19) : 1791 - 1800
  • [10] Perioperative Hemostatic Management of Patients Treated with Vitamin K Antagonists
    Levy, Jerrold H.
    Tanaka, Kenichi A.
    Dietrich, Wulf
    [J]. ANESTHESIOLOGY, 2008, 109 (05) : 918 - 926
12